These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31545250)

  • 1. High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment.
    Zhang Z; Zhou Z; Zhang M; Gross N; Gong L; Zhang S; Lei D; Zeng Q; Luo X; Li G; Li X
    Biomed Pharmacother; 2019 Oct; 118():109306. PubMed ID: 31545250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and chemotherapeutic implications of a novel four-gene pyroptosis model in head and neck squamous cell carcinoma.
    Yuan P; Jiang S; Wang Q; Wu Y; Jiang Y; Xu H; Jiang L; Luo X
    PeerJ; 2024; 12():e17296. PubMed ID: 38756442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
    Theile D; Gal Z; Warta R; Rigalli JP; Lahrmann B; Grabe N; Herold-Mende C; Dyckhoff G; Weiss J
    Cancer Biol Ther; 2014 Apr; 15(4):436-42. PubMed ID: 24448417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Notch1 expression and activation to cisplatin-sensitivity of head and neck squamous cell carcinoma.
    Zhang ZP; Sun YL; Fu L; Gu F; Zhang L; Hao XS
    Ai Zheng; 2009 Feb; 28(2):100-3. PubMed ID: 19550121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
    Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
    Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
    Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma.
    Gu F; Ma Y; Zhang Z; Zhao J; Kobayashi H; Zhang L; Fu L
    Oncol Rep; 2010 Mar; 23(3):671-6. PubMed ID: 20127005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
    Wang Y; Wang ZQ; Jiang YX; Wang FH; Luo HY; Liang Y; Wang DS; Li YH
    Expert Opin Pharmacother; 2016 Aug; 17(12):1585-90. PubMed ID: 27328125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma.
    Lee SH; Do SI; Lee HJ; Kang HJ; Koo BS; Lim YC
    Lab Invest; 2016 May; 96(5):508-16. PubMed ID: 26927514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch1 regulates invasion and metastasis of head and neck squamous cell carcinoma by inducing EMT through c-Myc.
    Inamura N; Kimura T; Wang L; Yanagi H; Tsuda M; Tanino M; Nishihara H; Fukuda S; Tanaka S
    Auris Nasus Larynx; 2017 Aug; 44(4):447-457. PubMed ID: 27595504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines.
    Landgraf V; Griessmann M; Roller J; Polednik C; Schmidt M
    Anticancer Res; 2019 Jul; 39(7):3633-3639. PubMed ID: 31262889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Notch1 increases paclitaxel sensitivity to human breast cancer.
    Zhao L; Ma Y; Gu F; Fu L
    Chin Med J (Engl); 2014; 127(3):442-7. PubMed ID: 24451948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
    Theile D; Ketabi-Kiyanvash N; Herold-Mende C; Dyckhoff G; Efferth T; Bertholet V; Haefeli WE; Weiss J
    Head Neck; 2011 Jul; 33(7):959-68. PubMed ID: 20737486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Li SH; Lin WC; Huang TL; Chen CH; Chiu TJ; Fang FM; Huang WT; Hsu CM; Luo SD; Lai CC; Su YY; Chuang HC; Chien CY
    Head Neck; 2016 Apr; 38 Suppl 1():E844-52. PubMed ID: 25917382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
    Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
    Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
    Sakakibara A; Tsukuda M; Kondo N; Ishiguro Y; Kimura M; Fujita K; Takahashi H; Matsuda H
    Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HEY1 is expressed independent of NOTCH1 and is associated with poor prognosis in head and neck squamous cell carcinoma.
    Rettig EM; Bishop JA; Agrawal N; Chung CH; Sharma R; Zamuner F; Li RJ; Koch WM; Califano JA; Guo T; Gaykalova DA; Fakhry C
    Oral Oncol; 2018 Jul; 82():168-175. PubMed ID: 29909892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.